Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema versus placebo and monocomponents in adults with overweight or obesity
NL-OMON53435Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of cagrilintide, semaglutide and CagriSema in obesity and Overweight, sponsored by Novo Nordisk. Primary endpoints: Relative change in body weight and Achievement of at least 5% weight reduction. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON53435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53435.